"At Nebraska Hematology Oncology, we’re a team here to take care of you. Our clinic works as a team to maintain open and honest communication, working ethically to challenge the building of knowledge to continue to support our patients. At Nebraska Hematology-Oncology, we believe that to best treat the disease we must first care for the person. We develop customized treatment programs based on the type and state of the cancer and the characteristics of the individual. So please, familiarize yourself with our clinic and rely on the team you can trust."

During the past decade, Nebraska Hematology and Oncology conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 44 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 36 clinical trials were completed. i.e. 360% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nebraska Hematology and Oncology" #1 sponsor was "National Cancer Institute (NCI)" with 23 trials, followed by "SWOG Cancer Research Network" with 17 trials sponsored, "Alliance for Clinical Trials in Oncology" with 8 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nebraska Hematology and Oncology" #1 collaborator was "National Cancer Institute (NCI)" with 30 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "NRG Oncology" with 3 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Nebraska Hematology and Oncology" are "Breast Cancer" (11 trials), "Recurrent Squamous Cell Lung Carcinoma" (9 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Recurrent Melanoma" (4 trials) and "Stage IIIC Cutaneous Melanoma AJCC v7" (4 trials). Many other conditions were trialed in "Nebraska Hematology and Oncology" in a lesser frequency.

Most popular intervention types in "Nebraska Hematology and Oncology" are "Drug" (72 trials), "Other" (44 trials), "Biological" (27 trials), "Radiation" (5 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (28 trials), "Quality-of-Life Assessment" (10 trials), "Docetaxel" (8 trials), "Ipilimumab" (8 trials) and "Nivolumab" (8 trials). Other intervention names were less common.

The vast majority of trials in "Nebraska Hematology and Oncology" are 72 trials for "All" genders, 11 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Nebraska Hematology and Oncology". undefined are not yet recruiting, 13 are recruiting, 36 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 27 completed trials in Nebraska Hematology and Oncology, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Nebraska Hematology and Oncology, 3 "Phase 1" clinical trials were conducted, 38 "Phase 2" clinical trials and 47 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".